"We believe that Acadia has an emerging pipeline with five promising clinical programs targeting large
Genzyme (GENZ) published results of a clinical trial involving its drug Tolevamer for diarrhea caused by the bacteria Clostridium difficile, sending the shares 1.3% higher to $67.37.
According to data from the trial, in which 300 patients received either Genzyme's Tolevamer or the antibiotic vancomycin, patients saw similar results, with the results indicating a possible reduction in the recurrence rate with the Genzyme drug. Vancomycin is currently the only FDA-approved drug to treat the infection.Biopharmaceutical company Novavax (NVAX - Get Report) shares were up 13% to $3.21 after an upgrade from RBC Capital Markets. While analyst Ken Trbovich notes that the company's quarterly results were weaker than expected, "with the stock trading near $3 per share, it no longer carries the significant downside risk that lead us to rate NVAX shares underperform," Trbovich wrote. The analyst raised his rating on the stock to sector-perform. Among other health stocks on the move were Hospira (HSP), down 1.9% to $34.80, Tenet Healthcare (THC - Get Report), whose shares sank 3.4% to $7.29, and Novogen (NVGN), whose stock was 2.2% lower at $10.22. Elsewhere, Osteotech (OSTE) gained 7.1% to $3.92, Cytokinetics (CYTK) was up 5.9% to $5.59, CAS Medical Systems (CASM) rose 4.8% to $6.07, New River Pharmaceuticals (NRPH) soared 13.8% to $26.20, Rotech Healthcare (ROHI) climbed 3.3% to $1.25, and AMN Healthcare Services (AHS) was up 1.5% to $22.24.